Several recent advances have provided new insights and possibilities in defining
therapeutic targets for Alzheimer's disease. Of particular importance is the identification of …

Degenerative diseases of the brain were long considered among the most obscure and
intractable of human maladies. However, recent advances in understanding their …

Converging lines of evidence implicate the beta‐amyloid peptide (Aβ) as causative in
Alzheimer's disease. We describe a novel class of compounds that reduce Aβ production by …

Cerebral deposition of amyloid plaques containing amyloid β-peptide (Aβ) has traditionally
been considered the central feature of Alzheimer's disease (AD). Aβ is derived from amyloid …

Summary β-Secretase (memapsin 2, BACE1) is an attractive target for the development of
inhibitor drugs to treat Alzheimer's disease (AD). Not only does this protease function at the …

Pathological, genetic, biochemical and pharmacological studies support the hypothesis that
brain accumulation of oligomeric species of β-amyloid (Aβ) peptides may cause Alzheimer's …

Research over the past ten years on Alzheimer's disease has pursued many opportunities.
Notable amongst the various approaches are efforts related to the “amyloid hypothesis.” This …

Rapid progress in deciphering the biological mechanism of Alzheimer's disease (AD) has
arisen from the application of molecular and cell biology to this complex disorder of the …

Mind how you go: The current strategies for the development of therapies for Alzheimer's
disease are very diverse. Particular attention is given to the search for inhibitors (see picture …

In the nonamyloidogenic processing pathway the Alzheimer's amyloid precursor protein
(APP) is proteolytically cleaved by α-secretase. As this cleavage occurs at the Lys16-Leu17 …